United States Patent & Trademark Office Grants Pfizer Reissue Patent For Celebrex® (celecoxib capsules)

  United States Patent & Trademark Office Grants Pfizer Reissue Patent For
  Celebrex® (celecoxib capsules)

Business Wire

NEW YORK -- March 5, 2013

Pfizer Inc. announced today that the United States Patent & Trademark Office
has granted Pfizer a reissue patent (U.S. Patent No. RE44048), covering
methods of treating osteoarthritis and other approved conditions with
celecoxib, the active ingredient in Celebrex^®. The reissue patent will expire
on December 2, 2015, which includes six months of pediatric exclusivity. The
basic patent for celecoxib expires on May 30, 2014, which also includes six
months of pediatric exclusivity.

“Continued development of new medicines that enhance patient lives is
supported by protecting intellectual property and innovation,” said Amy
Schulman, executive vice president and general counsel for Pfizer. "We are
pleased with the reissuance of this patent protecting the invention of using
celecoxib to treat osteoarthritis and other approved conditions, and have
initiated legal proceedings to enforce our intellectual property rights
through December 2, 2015.”

Pfizer filed suit today against Teva Pharmaceuticals USA, Inc., Mylan
Pharmaceuticals Inc., Watson Laboratories, Inc., Lupin Pharmaceuticals, USA,
Inc., Apotex Corp., and Apotex, Inc. in the United States District Court for
the Eastern District of Virginia for infringement of the reissue patent. Each
of these generic companies previously filed an abbreviated new drug
application with the United States Food and Drug Administration seeking
approval to market a generic form of celecoxib in the United States beginning
in May 2014, prior to the December 2, 2015 expiration of the reissue patent.

Contact:

Pfizer Inc.
Media Relations
Chris Loder, 212-733-7897
or
Investor Relations
Suzanne Harnett, 212-733-8009